|
| Press Releases |
|
 |
|
| Thursday, June 21, 2018 |
|
|
AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL |
| AbbVie GK and Eisai Co., Ltd. announced that HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL, a new pediatric formulation of HUMIRA, a fully human anti-TNF-alpha monoclonal antibody formulation, has been launched today after being listed in the National Health Insurance reimbursement price list on June 15. more info >> |
|
| Thursday, June 14, 2018 |
|
|
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research |
| Eisai Co., Ltd. announced today that its research subsidiary KAN Research Institute, Inc. has entered into an industry-academia-government joint research agreement with six joint research organizations concerning the "nucleic drug discovery research using novel nucleic acid synthesis and delivery technologies" research project represented by KAN. more info >> |
|
| Wednesday, June 13, 2018 |
|
|
Eisai to Establish New Research Facility "Eisai Center for Genetics Guided Dementia Discovery" in Cambridge, Massachusetts, USA |
| Eisai Co., Ltd. has announced that it has decided to establish the Eisai Center for Genetics Guided Dementia Discovery (G2D2), a new exploratory research facility focused on immuno-dementia based on human genetics, aimed at innovative drug discovery in the field of dementia, in Cambridge, Massachusetts, the United States. more info >> |
|
| Monday, June 11, 2018 |
|
|
AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA |
| The newly launched pen-type auto-injector devices were developed to simplify the operation and reduce the burden on patients when performing self-injection. more info >> |
|
| Wednesday, June 6, 2018 |
|
|
Eisai: Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting |
| Eisai Co., Ltd. and Purdue Pharma L.P. presented the results of two key Phase I clinical studies (Study 108 and Study 106) of their investigational sleep/wake regulation agent lemborexant at the 32nd Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2018), from June 2 to 6 in Baltimore, Maryland, the United States. more info >> |
|
| Tuesday, June 5, 2018 |
|
|
Eisai: PhaseII Clinical Study of Elenbecestat Demonstrate Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months |
| Eisai Co., Ltd. and Biogen Inc. announced today that elenbecestat was generally safe and well tolerated in a Phase II clinical study (Study 202) of the oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) conducted in the United States, and the results demonstrated a statistically significant difference in amyloid beta (AB) levels in the brain measured by amyloid-PET (positron emission tomography). more info >> |
|
| Monday, June 4, 2018 |
|
|
Eisai and Merck Announce Data at 2018 ASCO Annual Meeting |
| The data are included in presentations at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 1-5. LENVIMA and KEYTRUDA are not approved for use in combination in any cancer types today. more info >> |
|
| Thursday, May 31, 2018 |
|
|
U.S. FDA Designates for Priority Review of Eisai's Supplemental New Drug Application for Antiepileptic Drug Fycoma |
| Eisai Co., Ltd. has announced the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Eisai's antiepileptic drug (AED) Fycompa (perampanel). more info >> |
|
| Monday, May 28, 2018 |
|
|
Eisai: PIII Clinical Study Data on Chronic Constipation Treatment "GOOFICE 5mg Tablet" will be Presented at DDW2018 |
| Eisai Co., Ltd., Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. announce that an oral presentation on PIII clinical study data on "GOOFICE 5mg Tablet". more info >> |
|
| Friday, May 25, 2018 |
|
|
Eisai: Potent New Mechanism of Action for Treatment of Inflammatory Bowel Disease |
| This novel mechanism of action elucidated is expected to lead to value enhancement and acceleration of the development of E6007 which aims to provide a new remedy for IBD patients. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Local designer brands featured at 'Fashion Hong Kong Pop-up Salon' in Milan
Apr 3, 2025 08:00 HKT/SGT
|
|
|
Prideone Entertainment Announces New Post-War Film to Commemorate the 80th Anniversary of World War II's End
Apr 3, 2025 7:00 JST
|
|
|
3rd Future Cross Border Payments Summit, Dubai 2025: Trends Shaping the Future of Payments
Apr 2, 2025 22:03 HKT/SGT
|
|
|
Doubleview Gold Corp 2025 Exploration Program
Apr 2, 2025 21:00 HKT/SGT
|
|
|
Hola Prime Launches Industry-First One-on-One Mentorship from Market Experts 
Apr 2, 2025 20:00 HKT/SGT
|
|
|
Innovation Beverage Group Expands U.S. Distribution of its Award-Winning Bitters Through One of the Nation's Largest Beverage Alcohol Distributors
Apr 2, 2025 19:00 HKT/SGT
|
|
|
"GTF Advantage" Engine Achieved FAA Type Certification
Apr 2, 2025 17:41 JST
|
|
|
Expert Systems Expands Managed Services Offerings
Apr 2, 2025 16:33 HKT/SGT
|
|
|
Accelerated Transformation of New Quality Productive Forces with Growing Efficacy in Sci-Tech Innovation Layout
Apr 2, 2025 14:39 HKT/SGT
|
|
|
Euro Manganese Announces Upsize to Previously Announced Financing of up to C$11.2m (A$12.3m) including a Private Placement with Eric Sprott
Apr 2, 2025 14:10 HKT/SGT
|
|
|
CISO Indonesia 2025: Elevating Cybersecurity Strategies for a Resilient Digital Future
Apr 2, 2025 14:00 HKT/SGT
|
|
|
EdgePoint Towers Appoints Ravin Vickneswaran as Chief Operating Officer
Apr 2, 2025 11:00 HKT/SGT
|
|
|
Avenix Fzco Introduces Avexbot: Data-Driven Precision for Forex Traders
Apr 2, 2025 08:00 HKT/SGT
|
|
|
Wuling Motors (00305.HK) Achieves a Surge of 115.6% in Net Profit Attributable to Shareholders for 2024
Apr 1, 2025 21:53 HKT/SGT
|
|
|
Baguio Green Group Announces 2024 Annual Results
Apr 1, 2025 20:19 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
